Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) will announce its Q4 and full year 2020 financial results on February 18, 2021, after market close. A conference call will follow at 4:30 PM ET. The company focuses on developing OC-01 (varenicline) nasal spray for treating dry eye disease, a condition affecting over 30 million people in the U.S. Despite its potential, OC-01 remains an investigational drug, with safety and efficacy not yet established.

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 18, 2021, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time.

Conference Call Details
To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 2066335. A telephone replay will be available for approximately 7 days following the live conference call. To access the telephone replay, please dial (855) 859-2056 (US/Canada) or (404) 537-3406 (International). The conference ID number is 2066335.

Webcast Details
The webcast will be made available on the company’s website at www.oysterpointrx.com under the “Events & Presentations” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the live audio webcast.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.

About Dry Eye Disease
Dry eye disease is a chronic, progressive condition that impacts more than 30 million people in the United States and is growing in prevalence. An estimated 16 million adults in the U.S. have been diagnosed with dry eye disease, a multifactorial condition of the ocular surface characterized by disruption of the tear film. A healthy tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components to reduce the risk of infection, and creates a smooth surface that contributes refractive power for clear vision. Dry eye disease can have a significant impact on a person’s day-to-day quality of life, as it can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision and eye fatigue. Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com 

Media Contact: 
Sheryl Seapy, W2O Group
(213) 262-9390
sseapy@w2ogroup.com 

FAQ

What are the financial results for OYST for 2020?

Oyster Point Pharma will report its financial results for Q4 and the full year 2020 on February 18, 2021.

What is OC-01 nasal spray and its status?

OC-01 (varenicline) nasal spray is an investigational drug being developed by Oyster Point Pharma to treat dry eye disease.

When is the conference call for OYST's financial results?

The conference call for Oyster Point Pharma's financial results is scheduled for February 18, 2021, at 4:30 PM ET.

Where can I access the webcast of OYST's conference call?

The webcast can be accessed on Oyster Point Pharma's website under the 'Events & Presentations' section.